What's Your Take? Perspectives on Immunotherapy for Early-Stage Solid Tumors
Did you know? Immunotherapy is now being used for the neoadjuvant and adjuvant treatment of solid tumors -- find out more here!
This activity is intended for oncologists, surgeons, pathologists, and other clinicians on the multidisciplinary cancer care team.
The goal of this activity is for learners to be better able to understand the role of immunotherapy for the management of early-stage solid tumors and how best to care for patients with these cancer types in clinical practice.
Available beginning: February 14, 2023
Developed through a partnership between SITC and Medscape.
 |
 |
- This activity is intended for oncologists, surgeons, pathologists, and other clinicians on the multidisciplinary cancer care team. The goal of this activity is for learners to be better able to understand the role of immunotherapy for the management of early-stage solid tumors and how best to care for patients with these cancer types in clinical practice.
- Have increased knowledge regarding the clinical trial data evaluating immunotherapy in early-stage solid tumors
- Self-assess learning needs related to the care of patients with early-stage solid tumors as part of the multidisciplinary team
AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit: 0.25